Announcements
- ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
- ProMIS Neurosciences Issues Letter to Shareholders
- ProMIS Neurosciences, Inc. Announces Leadership Transition
More ▼
Key statistics
On Friday, ProMIS Neurosciences Inc (23J0:FRA) closed at 1.71, 97.69% above the 52 week low of 0.865 set on Dec 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.71 |
---|---|
High | 1.71 |
Low | 1.71 |
Bid | 1.65 |
Offer | 1.74 |
Previous close | 1.55 |
Average volume | 101.10 |
---|---|
Shares outstanding | 18.96m |
Free float | 14.35m |
P/E (TTM) | -- |
Market cap | 34.98m USD |
EPS (TTM) | -0.8292 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:00 BST.
More ▼